^
    27d
    Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations. (PubMed, NPJ Precis Oncol)
    Using patient-derived organoids (PDOs), we demonstrated that FGFR-amplified PDOs respond to fulvestrant, palbociclib, and rogaratinib only when PIK3CA and ESR1 are wild-type. Toxicity was manageable and consistent with prior data. Our findings highlight biomarker-driven approaches as essential for refining FGFR-targeted strategies in this resistant population.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR positive + ESR1 wild-type
    |
    Ibrance (palbociclib) • fulvestrant • rogaratinib (BAY 1163877)